Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, F-18-labeled [Nle(14),Lys(40)]exendin-4 analog, shows promise for clinical imaging by Mikkola, Kirsi et al.
ORIGINAL RESEARCH Open Access
Low kidney uptake of GLP-1R-targeting,
beta cell-specific PET tracer, 18F-labeled
[Nle14,Lys40]exendin-4 analog, shows
promise for clinical imaging
Kirsi Mikkola1,2*, Cheng-Bin Yim1,3, Paula Lehtiniemi1, Saila Kauhanen1,4, Miikka Tarkia5, Tuula Tolvanen1,6,
Pirjo Nuutila1,7 and Olof Solin1,8,9
Abstract
Background: Several radiometal-labeled, exendin-based tracers that target glucagon-like peptide-1 receptors
(GLP-1R) have been intensively explored for β cell imaging. The main obstacle has been the high uptake of tracer
in the kidneys. This study aimed to develop a novel GLP1-R-specific tracer, with fluorine-18 attached to exendin-4,
to label β cells for clinical imaging with PET (positron emission tomography). We hypothesized that this tracer
would undergo reduced kidney uptake. 18F-labeled [Nle14,Lys40]exendin-4 analog ([18F]exendin-4) was produced
via Cu-catalyzed click chemistry. The biodistribution of [18F]exendin-4 was assessed with ex vivo organ γ-counting
and in vivo PET imaging. We also tested the in vivo stability of the radiotracer. The localization of 18F radioactivity
in rat and human pancreatic tissue sections was investigated with autoradiography. Receptor specificity was assessed
with unlabeled exendin-3. Islet labeling was confirmed with immunohistochemistry. The doses of radiation in humans
were estimated based on biodistribution results in rats.
Results: [18F]exendin-4 was synthesized with high yield and high specific activity. Results showed specific, sustained
[18F]exendin-4 uptake in pancreatic islets. In contrast to previous studies that tested radiometal-labeled exendin-based
tracers, we observed rapid renal clearance of [18F]exendin-4.
Conclusions: [18F]exendin-4 showed promise as a tracer for clinical imaging of pancreatic β cells, due to its high
specific uptake in native β cells and its concomitant low kidney radioactivity uptake.
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Background
The determination of β cell mass is a challenge, because
the target is a diffuse collection of cell clusters, highly
dispersed throughout the pancreas. Indeed, the β cell
mass constitutes less than 2% of the total pancreas mass,
and this mass is likely to decrease during the course of
diabetes. The ongoing development of therapeutic ap-
proaches to diabetes, whether based on pharmacology or
islet transplantation, also calls for the development of
methods for longitudinal in vivo assessments of β cell
mass and function. There is an unmet need for an
imaging agent that offers potential for clinical trial
applications.
Glucagon-like peptide-1 (GLP-1) is secreted from the
intestine in response to elevated blood glucose levels.
GLP-1 binds to specific receptors on pancreatic islets to
stimulate insulin secretion. Exendin-4 is a long-acting
agonist of the glucagon-like peptide-1 receptor (GLP-1R);
it mimics the actions of short-lived GLP-1 (plasma half-
life <2 min). Several efforts have been made to label
pancreatic β cells with exendin-based tracers that carry
radiometals, such as 99mTc and 111In for SPECT imaging
[1, 2] and 64Cu and 68Ga for PET imaging [3]. However,
high radioactivity concentrations were observed in the
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kidney. During imaging, this high radioactivity compro-
mises tissue visualization in the kidney region, limits
quantitative imaging, and reduces diagnostic accuracy.
Because the kidney is a radiosensitive organ, the radiation
burden might rapidly become unacceptably high with
long-lived radioisotopes [4]. Some success has been
achieved in efforts to reduce the renal radioactivity of
various radiolabeled peptides. For example, some studies
co-administered amifostine, albumin derivatives, poly-
glutamic acid, or Gelofusine [5–7] to limit renal uptake;
and others used cleavable linkers, to allow excretion of
radioactive metabolites into the urine [8, 9].
Most peptides are excreted via the kidneys, but studies
have shown that persistent retention is characteristic
for radiometal-labeled exendin derivatives [10]. As an
alternative, preclinical studies were conducted with 18F-
labeled exendin-4; they showed high, sustained tracer
uptake in INS-1 tumor cells and xenograft models [11].
However, importantly, after initially high radioactivity
levels in the kidneys, clearance from the kidneys was
rapid, compared to radiometal-labeled analogs [12, 13].
Wu et al. [14] observed specific uptake of [18F]TTCO-
Cys40-exendin-4 in islets transplanted into NOD/SCID
mice but limited kidney retention. These results suggested
a need for further development of [18F]exendin-4 analogs
for clinical applications.
The present study aimed to develop a 18F-labeled
[Nle14,Lys40]exendin-4 tracer ([18F]exendin-4) via copper-
catalyzed click chemistry. This tracer could be clinically
useful for imaging pancreatic β cells to calculate mass. To
date, no optimal tracers are available for this application.
The vesicular monoamine transporter type II (VMAT2)
has been suggested as a target to calculate β cell mass,
but so far issues with this approach remain controver-
sial [15–17].
Methods
Precursors and radiochemistry
Tosyl-propargyl-triethylene glycol 1 was purchased
from Huayi Isotope Co. (Toronto, Canada) (Fig. 1).
Exendin-4-azide 2 was purchased from Peptide
Specialty Laboratories GmbH (Heidelberg, Germany).
Its amino acid sequence is HGEGTFTSDLSKQBEE
EAVRLFIEWLKNGGPSSGAPPPSZ (B = norleucine and
Z = azido-lysine-amide). [19F]Exendin-4 was synthesized
from [19F]fluoro-propargyl-triethylene glycol (ABX GmbH,
Radeberg, Germany) and peptidyl azide 2 following Cu(I)-
catalyzed alkyne/azide cycloaddition in tetrahydrofuran
(THF)/water, using aqueous solution of copper sulfate/
sodium ascorbate. [19F]Exendin-4 was isolated by high-
performance liquid chromatography (HPLC) (Jupiter
C12 semi-preparative column, Phenomenex, Torrance,
CA, USA).
Aqueous [18F]fluoride was produced by proton bom-
bardment of 18O-enriched water as reported previously
[18]. Synthesis started by allowing tosylate 1 to react
with a [18F]fluoride-Kryptofix complex in anhydrous
DMSO (Fig. 1). After purification by HPLC, the col-
lected fraction was concentrated on an Oasis HLB cart-
ridge (Waters, Milford, MA, USA). After elution of the
cartridge with THF, the obtained [18F]fluoro-propargyl-
triethylene glycol was allowed to react with peptidyl azide
2 in the presence of pre-activated copper sulfate/sodium as-
corbate for 10 min at room temperature. Subsequently, the
reaction mixture was diluted in water and purified by
HPLC. The collected fraction was retained on a Sep-Pak
C8 cartridge (Waters) and formulated in ethanol/saline.
Radiochemical analysis of 18F-labeled [Nle14,Lys40]exendin-
4 ([18F]exendin-4) was performed with HPLC and thin layer
chromatography (TLC). The reaction details and a full
characterization of the tracer will be reported elsewhere.
Fig. 1 Production of [18F]exendin-4. 18F-fluoride (aqueous) and tosylate (1) were combined in a nucleophilic reaction for 18F-prelabeling; the
product, 18F-fluoro-propargyl-triethylene glycol, was attached to exendin-4-azide (2) via Cu(I)-catalyzed alkyne/azide cycloaddition to produce
radiofluorinated exendin-4
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Experimental animals and tissue samples of human
pancreas
Sprague–Dawley rats (285 ± 30 g, N = 43) were obtained
from the Central Animal Laboratory, University of Turku.
Finnish landrace pigs (33 ± 3 kg, N = 3) were obtained
from a local farmer. The animal experiments were ap-
proved by the animal experiment board of the University
of Turku and by the State Provincial Office of Southern
Finland (ESAVI/3899/04.10.07/2013, ESAVI/823/04.10.07/
2013). Human pancreatic tissue was obtained from one
subject (woman, 36 years old), who had undergone a
pancreatic resection (pancreatic mucinous neoplasm) at
Turku University Hospital (Turku, Finland). Approval for
the use of human pancreatic tissue was obtained from the
Ethics Committee of the Hospital District of Southwest
Finland (ETMK 42/180/2008). The subject provided writ-
ten informed consent before participating in the study.
Small-animal PET imaging
The in vivo kinetics of [18F]exendin-4 were evaluated
with the Inveon Multimodality PET/CT scanner (Siemens,
Knoxville, TN, USA). Rats were anesthetized with isoflur-
ane/O2 and injected intravenously (i.v.) with [
18F]exendin-
4 (radioactivity 23 ± 5 MBq/kg, mass 2 ± 1 μg/kg). PET
scans were acquired for up to 6 h (dynamic 0–60 min;
static 210–240 min and 330–360 min; N = 2–5 rats/scan).
The data were reconstructed with the ordered subset
expectation maximization OSEM2D algorithm. Analyses
were performed with Inveon Research Workplace 3 soft-
ware (Siemens), after defining the volumes of interest
(VOIs) on selected tissues.
Ex vivo biodistribution
Rats were anesthetized with isoflurane/O2 and injected
(i.v.) with [18F]exendin-4 (radioactivity 23 ± 5 MBq/kg,
mass 2 ± 1 μg/kg). After injection, animals were allowed
to recover from the anesthesia (except animal sacrificed
15 min p.i.). We further investigated tracer distribution
in the brain by injecting one rat with a highly radioactive
dose (50 MBq) of [18F]exendin-4. Animals were sacri-
ficed at 15, 30, 60, 120, 240, and 360 min (N = 2–11
rats/time point). Blood was extracted, and selected or-
gans were dissected and weighed. Tissue radioactivity
was measured with a γ-counter (Wizard, PerkinElmer,
Turku, Finland). Tracer specificity was tested by co-
injecting radiolabeled exendin-4 with an excess of cold
exendin-3 (3 mg/kg) (Peptide Specialty Laboratories
GmbH). Measurements were corrected for radionuclide
decay, and results were reported as the percentage of the
injected dose of radioactivity per gram of tissue (%ID/g).
Ex vivo autoradiography
The kidney, pancreas, and brain were sectioned and ex-
posed to imaging plates (Fuji BAS-TR2025; Fuji Photo
Film Co., Tokyo, Japan) for approximately 4 h. Imaging
plates were scanned with a BAS-5000 scanner (Fuji Photo
Film Co.) and the images were analyzed with AIDA 4.5
software (Raytest, Isotopenmessgeräte, Straubenhardt,
Germany). Three pancreatic sections per rat were ana-
lyzed (N = 2–8 rats/time point). We determined the mean
density values (photostimulated luminescence per square
millimeter, PSL/mm2) of ten prominently labeled islets
and of the exocrine tissue and corrected for background
noise. Finally, the islet-to-exocrine tissue ratio was calcu-
lated. This was done in order to be able to demonstrate
the accumulation of radioactivity into the islets as a func-
tion of time and to be able to compare the islet-to-
exocrine tissue ratios between animals of different time
points. The pancreatic sections used for autoradiography
were then stained with insulin antibody (1’ mouse-anti-
insulin, Nordic Biosite, Täby, Sweden, 2’ MAHC1 mouse
probe, Biocare Medical, Concord, CA, USA), counter-
stained with hematoxylin, and imaged with a Slide Scanner
(Pannoramic 250 F, 3DHistech, Budapest, Hungary).
Metabolite assay
The metabolic stability of [18F]exendin-4 was evaluated
by radio-HPLC, as reported previously [3]. Briefly, sam-
ples were collected at 5, 15, 60, and 120 min post injec-
tion (p.i.; N = 1–3 samples/time point). Plasma and urine
proteins were precipitated with equivalent volumes of
acetonitrile and removed by centrifugation. Samples of
the pancreas, kidney, and duodenum (pyloric sphincter)
were homogenized in acetonitrile, purified by centrifuga-
tion, and the supernatants were analyzed with radio-
HPLC.
In addition, the stability of [18F]exendin-4 was deter-
mined in pig plasma. Prior to blood sampling, animals
were anesthetized (midazolam 1 mg/kg, xylazine 4 mg/
kg intramuscular), connected to a respirator, and venti-
lated mechanically. Anesthesia was maintained with an
i.v. infusion of propofol (10–20 mg/kg/h) and fentanyl
(4–8 μg/kg/h). Vital signs were monitored throughout the
study. Pigs were injected (radioactivity 1.2 ± 0.2 MBq/kg,
mass 0.14 ± 0.04 μg/kg) and blood was sampled at 5, 15,
30, 60, and 180 min p.i. (N = 3 samples/time point).
Plasma was treated and analyzed as described above.
In vitro [18F]exendin-4 binding in human and rat pancreas
and rat brain
We acquired a piece of human pancreas that was frozen
immediately after surgery. We dissected a rat pancreas
and brain and froze them immediately after dissection.
Prior to incubations with ligand, the tissue sections of
human and rat pancreas and GLP-1R-rich areas from
rat brain [19] were incubated for 30 min with 1% BSA
in PBS (pH 7.4). Then, sections were incubated for
60 min with various concentrations of [18F]exendin-4
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(range 2.5–20 nM) in vitro. To investigate tracer speci-
ficity, sections were incubated for 30 min with an ex-
cess of cold exendin-3 prior to adding [18F]exendin-4.
Sections were then washed and exposed to imaging plates,
as described above (ex vivo autoradiography). Next,
sections were stained and processed, as described above.
Estimation of radiation doses for humans
Absorbed doses were calculated with OLINDA/EXM1.0
software [20, 21], which includes radionuclide informa-
tion and a selection of human body phantoms. Rat ex
vivo biodistributions were estimated by integrating the
area under the time–activity curves. The obtained resi-
dence times were converted into corresponding human
values by multiplying with organ-specific factors that
scaled organs to body weights, as follows: (WTB,rat/WOr-
gan,rat) × (WOrgan,human/WTB,human), where WTB,rat and
WTB,human are the total body weights of rats and humans
(70-kg male), respectively; and WOrgan,rat and WOrgan,hu-
man are the organ weights of rats and humans (70-kg
male), respectively.
Statistical analyses
Results are reported as the mean ± SD. The two-tailed,
unpaired Student’s t test and one-way ANOVA were
used for determining statistical differences between
groups (GraphPad Prism 5.01, GraphPad Software, San
Diego, CA, USA). Linear regression analysis was used to
assess the relationship between the islet-to-exocrine tis-
sue ratio and time. Values of P < 0.05 were considered
statistically significant.
Results
Radiochemistry
The synthesis of [18F]exendin-4 is depicted in Fig. 1. The
copper(I)-catalyzed reaction between exendin-4-azide 2
and [18F]fluoro-propargyl-triethylene glycol proceeded
rapidly and efficiently under mild reaction conditions.
Technical details of the synthesis optimization studies
will be reported elsewhere. The absence of major radio-
active by-products ensured neat purification using
HPLC. Total synthesis time was approximately 1.5 h.
The average isolated yields of [18F]exendin-4 after HPLC
purification ranged from 14 to 338 MBq (at the end of
synthesis), when the starting amount of aqueous
[18F]fluoride was 2.5–18 GBq. The specific activity for
[18F]exendin-4 was 12–323 MBq/nmol at end of synthe-
sis, with a radiochemical purity exceeding 90%. Identity
of [18F]exendin-4 was confirmed by HPLC comparison
test with the cold standard.
Ex vivo biodistribution and PET imaging
Measurements of [18F]exendin-4 in tissue samples indi-
cated low but sustained uptake in the whole pancreas
over the course of the study (Fig. 2a, Table 1). [18F]exen-
din-4 accumulation in the kidneys was high at first, but
with time, its clearance was rapid and relatively little was
retained (Fig. 3). A co-injection of excess exendin antag-
onist did not significantly reduce the renal uptake of
[18F]exendin-4 (Table 1); this finding demonstrated that
kidney tracer uptake was not mediated by the GLP-1R.
In contrast, tracer uptake rates in the pancreas, lung,
and stomach wall were significantly reduced after the
exendin-3 injection, consistent with the expression pro-
file of GLP-1R in rat [22].
Dynamic imaging revealed increasing accumulation of
[18F]exendin-4 in the kidneys within minutes p.i., and
clearance had already begun in the late phase of the dy-
namic 60-min PET scan (Fig. 4a–b). Late static scans
showed rapid elimination via the kidneys. The lung and
stomach wall showed modest retention. Uptake in liver
was low, which indicated that the tracer was not metab-
olized via the hepatic pathway (Fig. 4c–d). Both ex vivo
biodistribution measurements and PET imaging showed
very low uptake in the brain.
Fig. 2 Ex vivo measurements of the accumulation of exendin-based tracers in rat pancreas. a In the pancreas (dashed line), the radioactivity uptake of
[18F]exendin-4 was rather constant over the course of the study (N = 2–11 rats/time point). b The [18F]exendin-4 uptake (highlighted with a blue box) in
the pancreas was significantly higher (P = 0.0001) than uptake of the 64Cu- and 68Ga-labeled PET tracer counterparts (one-way ANOVA) [3]. Conversely,
the uptake of the [111In]exendin-4 SPECT tracer (grey) was higher than uptake of the PET tracers [2]
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Analysis of tracer metabolites
In rat plasma, we detected unchanged [18F]exendin-4
and a more polar radioactive metabolite(s). The plasma
radioactivity associated with intact [18F]exendin-4 at
60 min p.i. represented 28.3 ± 3.5% of the total radio-
activity, and at 120 min p.i., this level decreased to 16%.
At 60 min p.i., [18F]exendin-4 represented 20 ± 7.2% of
the radioactivity in the pancreas, compared to 38 ± 3.5%
of the radioactivity in the duodenum, and negligible
levels of intact [18F]exendin-4 in the kidney and urine.
Additionally, in pigs, the plasma radioactivity associated
with [18F]exendin-4 at 5 min p.i. represented 87 ± 6% of
the radioactivity, and at 60 min p.i., this level decreased
to 77 ± 3%.
Effects of [18F]exendin-4 administration in pigs
In pigs, administration of [18F]exendin-4 raised the heart
rate from 100–110 beats/min to 230–250 beats/min and
Table 1 Ex vivo biodistribution of [18F]exendin-4 in rat
Differences between values at 60-min and 60-min blocking were determined with the Student t test without correction for multiple comparisons. One-way ANOVA
and Bonferroni’s multiple comparison test was used to determine the differences at 60, 120, 240, and 360 min. */†P < 0.05, **/††P < 0.01, and ***/†††P < 0.001 statistically
significant compared to [18F]exendin-4 at 60 min post injection. Results are expressed as the mean ± SD percentage of the injected dose per gram of tissue
Fig. 3 Ex vivo measurements of accumulation of exendin-based PET and SPECT tracers in rat kidney. The renal clearance of [18F]exendin-4 (blue)
was rapid, and the radioactivity in kidney was significantly lower at all investigated time points, compared to other, metal-labeled, exendin-based
tracers designed for PET and SPECT analyses [2, 3, 41]. Ex vivo autoradiography images (blue inset) show the decreasing [18F]exendin-4 accumulation in
the kidney cortex at 60, 120, and 360 min p.i.
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body temperature from 37 to 41 °C. The blood pressure
decreased, and arrhythmia was observed. Similar symp-
toms and effects of exendin on heart rate and blood
pressure have been reported previously [23].
Intrapancreatic distribution of [18F]exendin-4 in rats
After [18F]exendin-4 injections, tracer uptake was ob-
served in the islets of rat pancreas (Fig. 5a). Islet labeling
was not visible when rats were co-injected with excess
cold exendin-3 and [18F]exendin-4 (Fig. 5b–c). These re-
sults indicated that [18F]exendin-4 had bound specific-
ally to GLP-1R in the islets. The autoradiography results
demonstrated that [18F]exendin-4 was cleared from the
exocrine pancreas, but uptake was sustained in the islets.
These findings were reflected in the islet-to-exocrine tis-
sue ratio, which increased over time (Fig. 5d). These
findings were consistent with previous reports [3, 8]. In
contrast, our autoradiography results of rat brain did not
show any tracer uptake in the investigated GLP1-R-rich
areas after injections of either high (50 MBq) or low
(5 MBq) doses of radioactivity.
Similarly, islet labeling was observed in vitro, after in-
cubating rat pancreatic sections with [18F]exendin-4
(Fig. 6a–b). Islet labeling was not detected when excess
of cold exendin-3 was also added (Fig. 6c–d). Unlike the
tracer injections into living animals, the GLP-1R areas in
brain were clearly labeled after in vitro incubations with
[18F]exendin-4 (Fig. 7).
Tracer binding in tissue sections of human pancreas
We investigated tracer binding in human pancreas by in-
cubating pancreatic tissue sections with various concen-
trations of [18F]exendin-4. We found that tracer binding
was clearly visible in human pancreatic islets (Fig. 8a–b).
Islet binding was verified by immunostaining the same
sections to detect insulin. When excess cold exendin-3
was added with [18F]exendin-4, no [18F]exendin-4 binding
Fig. 4 In vivo retention and clearance of [18F]exendin-4 in rat. a Dynamic PET imaging revealed rapid tracer accumulation in the kidneys at early
time points and, thereafter, rapid elimination. Uptake in lung and stomach wall was modest. b Coronal PET/CT image at 0–60 min p.i. c Tracer
accumulation in the liver remained low. d Coronal PET/CT image at 360 min p.i. (N = 2–5 rats/scan)
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was observed in human pancreatic islet tissue sections
(Fig. 8c–d).
Dosimetry
By extrapolating from our rat ex vivo results, we calcu-
lated that the mean [18F]exendin-4 effective dose for a
70-kg human adult was 0.021 mSv/MBq (Table 2). The
kidney was the dose-limiting organ. When we based
calculations on the ex vivo results, the absorbed kidney
dose for [18F]exendin-4 was 0.3 mSv/MBq.
Discussion
This report described the synthesis of [18F]exendin-4
and its evaluation in rat and human pancreas. In this
study, ex vivo γ-counting of rat whole pancreas and
autoradiography analyses of pancreatic sections showed
specific and sustained uptake of [18F]exendin-4 in the is-
lets. In vitro labeling of human pancreas revealed specific
targeting of the islets and co-localization with insulin, de-
tected with immunohistochemistry. Renal clearance of
[18F]exendin-4 was rapid compared to radiometal-labeled
exendin derivatives [2, 3, 24, 25].
Fig. 5 Ex vivo [18F]exendin-4 uptake in rat pancreas and pancreatic islets. a Tracer uptake in islets was clearly visible at 60 min p.i. Uptake in islets
was verified by staining the same section with insulin antibody (upper right inset and lower right inset). b–c Tracer specificity was assessed by
co-injecting [18F]exendin-4 and excess cold exendin-3. d Towards longer time points, the high ratios indicated a significant difference in islet
labeling compared to background (N = 2–8 rats/time point). a–c Scale bars 2000 μm
Fig. 6 In vitro binding of [18F]exendin-4 in rat pancreas. a Clear tracer binding was observed after incubating pancreatic tissue sections with
[18F]exendin-4 (2.5 nM) b co-localization with the islets was observed by staining the same sections with insulin antibody. c–d Islet labeling was
not observed, when an excess of cold exendin-3 was added. Scale bar 1000 μm
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18F-labeled target-specific peptides are ideal in vivo
imaging agents, because 18F is readily available from
most small medical cyclotrons, and it has a half-life
(110 min) that matches the pharmacokinetics of most
peptides. Moreover, 18F decays with a 96% positron
branching ratio, and it has a short β+ trajectory (Eβmax =
635 keV), which enables the acquisition of high-
resolution PET images. Previous reports have described
various approaches for the radiofluorination of exendin-4
analogs, which utilize maleimide- or aldehyde-containing
prosthetic reagents, and chelating agents [13, 26–28].
However, the main challenge is designing an efficient
strategy for preparing radiotracers with very high specific
activity, which would render in vivo imaging of native β
cells. Click chemistry has generated increasing attention
due to its rapid and high-yielding transformation, and
tolerance to a broad range of functional groups. These
properties make click chemistry one of the preferred
strategies in developing 18F-labeled radiopharmaceuti-
cals [14, 29, 30]. The original copper-catalyzed variant
of the Huisgen 1,3-dipolar cycloaddition of terminal al-
kynes and azides features very high reaction rates [31, 32]
and has prompted us to advance this reaction into the de-
sign of a potential clinical grade tracer for native β cell im-
aging. It was shown previously that the binding affinity
(IC50) of native exendin-4 for GLP-1 receptor was not
Fig. 7 In vitro and ex vivo binding of [18F]exendin-4 in rat brain. a GLP-1R was clearly labeled in the lateral septum (LS) after incubating sections
of rat brain with tracer in vitro (1.25 nM). b No binding in the corresponding brain area was observed 60 min after intravenous injection of
[18F]exendin-4 (50 MBq). c For histological reference, the same section was stained with hematoxylin and eosin (HE). Scale bar 1000 μm
Fig. 8 Islet labeling in human pancreas after [18F]exendin-4 incubation in vitro. a–b Insulin immunohistochemistry confirmed that tracer binding
co-localized with the islets. c–d The specificity of [18F]exendin-4 to GLP-1R in the islets was demonstrated by incubating the sections with excess
cold exendin-3. Scale bars 1000 μm
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significantly altered by modification/addition of a fluori-
nated linker [14, 33]. Noteworthy, the different fluorin-
ation strategies did not affect the binding affinity of the
cold ligand towards the target receptor, compared to
native exendin-4.
The GLP-1R is expressed specifically in pancreatic β
cells [34, 35]; little to no expression was found on other
pancreatic islet cell types [36]. Because GLP-1R expres-
sion levels are low, a sensitive radiotracer with high spe-
cific activity is required to avoid receptor saturation with
unlabeled peptide [37]. The number of GLP-1Rs in
native β cells and transplanted islets is restricted com-
pared to insulinomas, which overexpress the receptor. In
this study, [18F]exendin-4 was produced with a specific
activity as high as 323 MBq/nmol and an injected mass
of 2 ± 1 μg/kg. In humans, the pharmacological dose of
exenatide (Byetta®) is low (10 μg BID), and in animal
studies, exendin-4 was a potent glucose-lowering agent
(dose 0.001 to 10 μg) [38]. These properties of high
specific activity and low injected radiotracer mass must
be considered carefully. With doses of 7–25 μg of
[68Ga]NOTA-exendin-4, subjects experienced palpita-
tion, vomiting, and nausea after tracer injection [39].
In previous studies, the levels of pancreatic uptake of
other labeled exendin-based tracers were similar at
60 min p.i. (Fig. 2b). Nevertheless, [18F]exendin-4 accu-
mulation in the pancreas was significantly higher than
that of the 64Cu- and 68Ga-labeled counterparts [3].
Brom et al. [2] showed that the [111In]DTPA-exendin-4
SPECT tracer was taken up by the pancreas at a higher
rate than the PET ligands.
Kastin et al. [40] reported that exendin-4 crossed the
blood–brain barrier in rat. In our studies, GLP-1R-rich
areas were observed in in vitro studies of rat brain sec-
tions (Fig. 7). However, ex vivo autoradiography, tissue
γ-counting, and PET imaging did not reveal any specific
binding in rat brain. These results indicated that
[18F]exendin-4 did not cross the blood–brain barrier.
Our stability study results demonstrated that the na-
tive (unmetabolized) tracer was recovered in significantly
higher amounts in pig plasma compared to rat plasma.
However, in rats [18F]exendin-4 was rapidly cleared from
the blood, and low amounts were taken up in the liver.
In contrast, when 18F-labeled GLP-1R targeting radio-
tracers were investigated in xenograft models, substan-
tial liver uptake was observed [11, 13, 14, 28]. On the
other hand, Yue et al. [12] reported moderate liver re-
tention of [18F]FNEM-[Cys40]-exendin-4 in a xenograft
model. High liver uptake might restrict the clinical use
of these tracers, because the liver is the site of insuli-
noma metastasis, and it is also the primary site for islet
transplantation. Low tracer accumulation in the liver en-
ables the high target-to-background contrast required
for high-quality PET imaging.
In this study, PET imaging and organ radioactivity
measurements demonstrated high [18F]exendin-4 uptake
in the kidneys soon after injection, but thereafter, clear-
ance was rapid and retention decreased (Fig. 3). In con-
trast, the renal excretion route and proximal tubular
reabsorption cause high retention of metal-labeled exen-
din tracers in the kidney cortex. At the 60-min time
point, kidney uptake of [18F]exendin-4 was significantly
lower than the uptake of the metal-labeled counterparts.
Furthermore, at several hours p.i., high levels of both
[111In]DTPA-exendin-4 [2, 41] and [64Cu]NODAGA-
exendin-4 [3] had accumulated at in the kidneys, and
[111In]DTPA-exendin-4 showed only minor clearance
over time. Consequently, repeated scanning in patients
could cause radiation doses that exceed the tolerance of
this delicate organ [4, 42]. Melis et al. [43] showed that
high radiation doses of [111In]DTPA-Lys40-exendin-4
caused nephrotoxicity in mice. Several approaches have
been tested to overcome high uptake of exendin-based
Table 2 Human radiation dosimetry estimates for 18F radioactivity
extrapolated from the rat ex vivo data
Organ Dose (mSv/MBq)
Adrenal glands 0.016
Brain 0.004
Breasts 0.004
Gallbladder wall 0.011
LLI wall 0.003
Small intestine 0.005
Stomach wall 0.007
ULI wall 0.005
Heart wall 0.010
Kidneys 0.300
Liver 0.026
Lungs 0.071
Muscle 0.005
Ovaries 0.003
Pancreas 0.023
Red bone marrow 0.009
Osteogenic cells 0.045
Skin 0.003
Spleen 0.022
Testes 0.001
Thymus 0.005
Thyroid 0.003
Urinary bladder wall 0.002
Uterus 0.003
Total body 0.009
Effective dose 0.021
LLI lower large intestine wall, ULI upper large intestine
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tracers in the kidneys, including co-administration of
competitive inhibitors of reabsorption [5–7], addition of
metabolizable linkers [8, 9], or modifications in the size,
charge, or structure of the tracer [44, 45]. Those attempts
have been crucial in finding ways to improve the imaging
accuracy, decrease the risk of nephrotoxicity, and improve
the efficacy of peptide receptor radionuclide therapy.
In this study, the absorbed kidney dose of [18F]exendin-4
was similar to that of [68Ga]Ga-DO3A-VS-Cys40-exendin-4
(Table 3) [46]. The absorbed kidney doses of 64Cu- and
111In-labeled tracers were 5 and 15 times higher, re-
spectively, than that of [18F]exendin-4. Furthermore,
the effective dose of [18F]exendin-4 was 4 and 7 times
lower than corresponding values for [64Cu]NODAGA-
exendin-4 and [111In]DTPA-exendin-4.
Conclusions
We found that in vivo injections of the β cell-specific
PET tracer, [18F]exendin-4, resulted in specific, sustained
tracer uptake in rat pancreatic islets. Additionally, we
demonstrated specific uptake of [18F]exendin-4 in hu-
man pancreatic tissues in vitro. Unlike its metal-labeled
counterparts, [18F]exendin-4 renal clearance was rapid.
These properties of [18F]exendin-4 showed promise
for its future development for use in clinical imaging
of β cells.
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